Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:SRRA

Sierra Oncology (SRRA) Stock Price, News & Analysis

Sierra Oncology logo

About Sierra Oncology Stock (NASDAQ:SRRA)

Advanced Chart

Key Stats

Today's Range
$54.99
$54.99
50-Day Range
$54.73
$54.99
52-Week Range
$14.91
$55.19
Volume
N/A
Average Volume
931,731 shs
Market Capitalization
$1.34 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is headquartered in San Mateo, California.

Receive SRRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sierra Oncology and its competitors with MarketBeat's FREE daily newsletter.

SRRA Stock News Headlines

Sierra Oncology Inc.
Elon’s 2025 Silver Crisis (What It Means for You)
Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless production of electric vehicles and solar technology is driving demand for the precious metal to unprecedented levels. Silver—critical for EV batteries, solar panels, and advanced electronics—is now at the center of a supply crisis.
Sierra Coupon for October
See More Headlines

SRRA Stock Analysis - Frequently Asked Questions

Sierra Oncology, Inc. (NASDAQ:SRRA) announced its quarterly earnings data on Friday, November, 5th. The biotechnology company reported ($2.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.78) by $0.32.

Based on aggregate information from My MarketBeat watchlists, some other companies that Sierra Oncology investors own include Onconova Therapeutics (ONTX), VBI Vaccines (VBIV), T2 Biosystems (TTOO), OPKO Health (OPK), Tonix Pharmaceuticals (TNXP), Trevena (TRVN) and Inovio Pharmaceuticals (INO).

Company Calendar

Last Earnings
11/05/2021
Today
5/28/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:SRRA
Previous Symbol
NASDAQ:DNAI
Fax
N/A
Employees
109
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$94.66 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$300,000.00
Price / Cash Flow
N/A
Book Value
$6.16 per share
Price / Book
8.93

Miscellaneous

Free Float
13,650,000
Market Cap
$1.34 billion
Optionable
Optionable
Beta
0.03

Social Links

20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (NASDAQ:SRRA) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners